… ProQR Announces Positive Top-Line Results from the Phase 1/2 … and CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research & Development of ProQR, said, “We are very pleased with the data reported from …
Study did not meet primary endpoint nor notable secondary endpoints – no benefit observed in either treatment arm versus shamAdditional analyses to be conducted and presented at a future medical congressSepofarsen continues to be generally well tolerated